Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective
详细信息 查看全文
- 作者：Anne Jansena ; Anne.FM.Jansen@radboudumc.nl" class="auth_mail" title="E-mail the corresponding author ; Marcel van Deurena ; Joanne Millerb ; Joanne.Miller@ouh.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; Jiri Litzmanc ; litzman@fnusa.cz" class="auth_mail" title="E-mail the corresponding author ; Javier de Graciad ; jgracia@vhebron.net" class="auth_mail" title="E-mail the corresponding author ; Matí ; as Sá ; enz-Cuestae ; matiasbernabe.saenzcuesta@osakidetza.net" class="auth_mail" title="E-mail the corresponding author ; Anna Szaflarskaf ; miszafla6@wp.pl" class="auth_mail" title="E-mail the corresponding author ; Timi Marteliusg ; timi.martelius@hus.fi" class="auth_mail" title="E-mail the corresponding author ; Yuichi Takiguchih ; takiguchi@faculty.chiba-u.jp" class="auth_mail" title="E-mail the corresponding author ; Smita Patelb ; Siraj Misbahb ; Anna Simona ; on behalf of the Good syndrome Study Group
- 关键词：BAFF-R ; B-cell activating factor receptor ; CMV ; Cytomegalovirus ; CVID ; common variable immunodeficiency ; ESID ; European Society for Immunodefiencies ; GS ; Good syndrome ; G-CSF ; Granulocyt e-Colony Stimulating Factor ; TACI ; Transmembrane activator and CAML interactor
- 刊名：Clinical Immunology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：171
- 期：Complete
- 页码：12-17
- 全文大小：459 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Follow-up data of 499 patient years of 47 GS patients was collected by questionnaires.
- class="label">•
Median age at diagnosis was 58 years and median follow up was 9 years per patient.
- class="label">•
Most patients (74%) experienced at least one lower respiratory tract infection.
- class="label">•
Median survival of this cohort of GS patients is 14 years.